Stock listing
NPCE Stock Price, News, Filings & Events — Neuropace, Inc.
Selected listing: NPCE · NASDAQ · USD · US
This page tracks Neuropace, Inc.'s NPCE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NPCE:NASDAQ. NPCE:NASDAQ is the stock-level entry point for investors researching Neuropace, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neuropace, Inc. (Ticker: NPCE) is a public company operating in the American market with a market capitalization of approximately $505 million. The company focuses on innovative solutions in the field of neurology. Neuropace is dedicated to improving patient outcomes through advanced medical technology.
- Ticker
- NPCE:NASDAQ
- Asset type
- Stock
- Market cap
- $481.6M
- Sector
- Health Technology
- Industry
- Medical Specialties
- Exchange
- NASDAQ
- Currency
- USD
Neuropace, Inc. NPCE:NASDAQ stock context
This page tracks Neuropace, Inc.'s NPCE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NPCE:NASDAQ. NPCE:NASDAQ is the stock-level entry point for investors researching Neuropace, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neuropace, Inc. (Ticker: NPCE) is a public company operating in the American market with a market capitalization of approximately $505 million. The company focuses on innovative solutions in the field of neurology. Neuropace is dedicated to improving patient outcomes through advanced medical technology.
Latest news from Neuropace, Inc.
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
July 28, 2026
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosur...
May 29, 2026
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
May 29, 2026
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
May 12, 2026
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
Neuropace, Inc. earnings calls
Neuropace, Inc. (NPCE) Q2 2026 Earnings Call
August 11, 2026 · Replay with transcript and chapters
Neuropace, Inc. (NPCE) Q1 2026 Earnings Call
May 12, 2026 · Replay with transcript and chapters
Neuropace, Inc. (NPCE) Q4 2025 Earnings Call
March 3, 2026 · Replay with transcript and chapters
Neuropace, Inc. (NPCE) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Neuropace, Inc. (NPCE) Q2 2025 Earnings Call
August 12, 2025 · Replay with transcript and chapters
Neuropace, Inc. (NPCE) Q1 2025 Earnings Call
May 13, 2025 · Replay with transcript and chapters
Research Neuropace, Inc.
Neuropace, Inc. investor report
Review AI stock analysis and investor report context for NPCE:NASDAQ.
Neuropace, Inc. company profile
View the public company page for Neuropace, Inc. on 6ix.
Neuropace, Inc. news
Read company news and market updates connected to Neuropace, Inc..
Neuropace, Inc. investor events
Find investor webinars, events, and replay context for Neuropace, Inc..